Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4852551rdf:typepubmed:Citationlld:pubmed
pubmed-article:4852551lifeskim:mentionsumls-concept:C0032961lld:lifeskim
pubmed-article:4852551lifeskim:mentionsumls-concept:C0029921lld:lifeskim
pubmed-article:4852551lifeskim:mentionsumls-concept:C0012471lld:lifeskim
pubmed-article:4852551lifeskim:mentionsumls-concept:C1554881lld:lifeskim
pubmed-article:4852551lifeskim:mentionsumls-concept:C1549081lld:lifeskim
pubmed-article:4852551lifeskim:mentionsumls-concept:C1692758lld:lifeskim
pubmed-article:4852551pubmed:issue1lld:pubmed
pubmed-article:4852551pubmed:dateCreated1974-11-11lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:languageenglld:pubmed
pubmed-article:4852551pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:citationSubsetIMlld:pubmed
pubmed-article:4852551pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4852551pubmed:statusMEDLINElld:pubmed
pubmed-article:4852551pubmed:monthJullld:pubmed
pubmed-article:4852551pubmed:issn0090-6980lld:pubmed
pubmed-article:4852551pubmed:authorpubmed-author:JouppilaPPlld:pubmed
pubmed-article:4852551pubmed:authorpubmed-author:YlikorkalaOOlld:pubmed
pubmed-article:4852551pubmed:authorpubmed-author:JärvinenP APAlld:pubmed
pubmed-article:4852551pubmed:authorpubmed-author:YlöstaloPPlld:pubmed
pubmed-article:4852551pubmed:issnTypePrintlld:pubmed
pubmed-article:4852551pubmed:day10lld:pubmed
pubmed-article:4852551pubmed:volume7lld:pubmed
pubmed-article:4852551pubmed:ownerNLMlld:pubmed
pubmed-article:4852551pubmed:authorsCompleteYlld:pubmed
pubmed-article:4852551pubmed:pagination57-70lld:pubmed
pubmed-article:4852551pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:4852551pubmed:otherAbstractPIP: Prostaglandin F2alpha (PGF2alpha) administered as single intrauterine injection was used for termination of very early pregnancy in 34 outpatients. 12 patients were induced with 1.0 mg, 18 patients with 2.0 mg and 4 patients with 4.0 mg of PGF2alpha. After 2 weeks, abortion was complete in 58% induced with 1.0 mg, in 78% induced with 2.0 mg, and in all 4 patients induced with 4.0 mg. After 3 weeks, abortion was complete in 83% induced with 1.0 mg and in 100% induced with 2.0 mg. There was 1 failure, which occurred in the group treated by using 1.0 mg PGF2alpha. Immediate side-effects were kept at an acceptable level with a very mild premedication. No serious complications occurred but curettage was performed on 2 patients because of bleeding. Spontaneous menstruation started in the 1.0 mg group within an average of 33 days (range 25-61). The use of 2.0 mg PGF2alpha for the routine termination of very early pregnancy is recommedned.lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:meshHeadingpubmed-meshheading:4852551-...lld:pubmed
pubmed-article:4852551pubmed:year1974lld:pubmed
pubmed-article:4852551pubmed:articleTitleIntrauterine injection of prostaglandin F2alpha for termination of early pregnancy in out-patient.lld:pubmed
pubmed-article:4852551pubmed:publicationTypeJournal Articlelld:pubmed